FMP
CNS Pharmaceuticals, Inc.
CNSP
NASDAQ
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
3.62 USD
-0.19 (-5.25%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. John Michael Climaco Esq., J.D.
sector
Healthcare
industry
Biotechnology
website
https://www.cnspharma.comexchange
NASDAQ
Description
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas...
CIK
0001729427
ISIN
US18978H4092
CUSIP
18978H409
Address
2100 West Loop South
Phone
800 946 9185
Country
US
Employee
3
IPO Date
Nov 8, 2019
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
CNSP Financial Summary
CIK
0001729427
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
18978H409
ISIN
US18978H4092
Country
US
Price
3.62
Beta
1.12
Volume Avg.
644.45k
Market Cap
9.92M
Shares
-
52-Week
2-975
DCF
3.29
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-
P/B
-
Website
https://www.cnspharma.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest CNSP News
It looks like there's no news available.
